Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations

INTRODUCTION: Alzheimer’s disease (AD) is one of the most common causes of dementia. Pathogenic variants in the presenilin 1 (PSEN1) gene are the most frequent cause of early-onset AD. Medications for patients with AD bearing PSEN1 mutation (PSEN1-AD) are limited to symptomatic therapies and no esta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Takayuki, Banno, Haruhiko, Okunomiya, Taro, Amino, Yoko, Endo, Kayoko, Nakakura, Akiyoshi, Uozumi, Ryuji, Kinoshita, Akemi, Tada, Harue, Morita, Satoshi, Ishikawa, Hidehiro, Shindo, Akihiro, Yasuda, Ken, Taruno, Yosuke, Maki, Takakuni, Suehiro, Takashi, Mori, Kohji, Ikeda, Manabu, Fujita, Koji, Izumi, Yuishin, Kanemaru, Kazutomi, Ishii, Kenji, Shigenobu, Kazue, Kutoku, Yumiko, Sunada, Yoshihide, Kawakatsu, Shinobu, Shiota, Shunji, Watanabe, Toshifumi, Uchikawa, Osamu, Takahashi, Ryosuke, Tomimoto, Hidekazu, Inoue, Haruhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246358/
https://www.ncbi.nlm.nih.gov/pubmed/34193504
http://dx.doi.org/10.1136/bmjopen-2021-051343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246358/
https://www.ncbi.nlm.nih.gov/pubmed/34193504
http://dx.doi.org/10.1136/bmjopen-2021-051343

Ejemplares similares